The objective of this study is to evaluate the side effects of intracavernous vasoactive agents on clinical and sonographic basis. Two groups of patients were included, group I included 168 ED ...

A 46-year-old man with type II diabetes, hypertension and dyslipidaemia and a 4-year history of erectile dysfunction, presented with a painful priapism 7 h following the administration of oral ...

Background. In March 2002, a patient in Tel Aviv, Israel, died of endocarditis caused by Phialemonium curvatum. As part of his therapy for erectile dysfunction, the patient had been trained to ...

Oct. 25, 2004 — A single subtherapeutic intracavernous injection of the human recombinant Maxi-K ion channel gene via a "naked DNA" plasmid vector (hMaxi-K) is safe in men with moderate to severe ...

Oral therapy is the simplest and most patient-friendly therapy that is currently available for the treatment of erectile dysfunction (ED). If treatment with an oral phosphodiesterase inhibitor is ...